{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "P",
                    "position": "30"
                },
                "variant_string_id": "SNCA A30P"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Point mutations in the a - synuclein protein sequence are associated with early - onset familial Parkinson's disease (PD), and wild - type a - synuclein accumulates within intracellular inclusions and abnormal neurites (Lewy bodies and Lewy neurites) in cases of sporadic PD. a - Synuclein aggregation is identified in neurodegenerative diseases, and the term synucleinopathy describes this spectrum of disorders sharing common synuclein pathology. The PLD enzymes are involved in various cellular processes such as vesicular transport, mitogenesis, etc., and a - synuclein and b - synuclein have been identified as specific inhibitors of PLD2.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly links a - synuclein mutations to Parkinson's disease and describes the role of PLD2, which is relevant to the functional assay of a - synuclein mutants' effect on PLD2 inhibition.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study uses an in - vitro assay to measure the inhibition of hPLD2 activity by wild - type and mutant synuclein proteins. The assay measures the release of [3H]choline from lipid vesicles by hPLD2 in the presence of synuclein proteins.",
                    "judgment": "Yes",
                    "reasoning": "The in - vitro assay of hPLD2 inhibition by synuclein proteins effectively models the potential role of a - synuclein in PD pathogenesis as it is related to the PLD2 - related function of a - synuclein.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Basic controls and replicates: Staining of eluates separated by SDS - PAGE with Coomassie brilliant blue showed a 105 kDa protein in infected, but not uninfected, cells (negative control). Wild - type and mutant synuclein proteins were used. The experiments were performed in multiple (three or four) separate experiments (replicates). Variant controls: Known pathogenic mutants (A53T) and wild - type (negative control) were used as controls.",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "judgment": "Yes",
                    "reasoning": "Both normal (wild - type) and abnormal (A53T, a known pathogenic mutant) controls were used, and the paper explicitly stated that multiple (three or four) replicates were used for the experiments.",
                    "next_step_or_outcome": "Proceed to Step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Known pathogenic mutant A53T and wild - type a - synuclein were used as controls in the assay for A30P.",
                    "sub_step": "3c: Variant Controls",
                    "judgment": "Yes",
                    "reasoning": "A known pathogenic variant (A53T) was used as a control in the assay for A30P.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "extracted_paper_info": "Statistical analysis of inhibition used the General Linear Model to perform analysis of covariates (ANCOVA) to compare slopes between proteins. However, no OddsPath was calculated in the paper for A30P.",
                    "sub_step": "4a: Statistical Analyses",
                    "judgment": "No",
                    "reasoning": "Although statistical analyses were done, no OddsPath was calculated for A30P.",
                    "next_step_or_outcome": "Proceed to Step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "extracted_paper_info": "The number of benign/pathogenic variant controls used across the entire study for A30P - related assay: Wild - type (benign) and A53T (pathogenic) were used. So, 2 controls in total.",
                    "sub_step": "4b: No OddsPath Calculation",
                    "judgment": "10 or less",
                    "reasoning": "Only 2 variant controls (wild - type and A53T) were used in the assay related to A30P.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for SNCA A30P is rated as PS3_supporting. The disease mechanism of Parkinson's disease related to a - synuclein and PLD2 function was defined. The in - vitro assay was applicable. Basic controls, replicates, and variant controls were used. However, without OddsPath calculation and with only 2 variant controls, the maximum strength of evidence is PS3_supporting."
        },
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "T",
                    "position": "53"
                },
                "variant_string_id": "SNCA A53T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Point mutations in the a - synuclein protein sequence are associated with early - onset familial Parkinson's disease (PD), and wild - type a - synuclein accumulates within intracellular inclusions and abnormal neurites (Lewy bodies and Lewy neurites) in cases of sporadic PD. a - Synuclein aggregation is identified in neurodegenerative diseases, and the term synucleinopathy describes this spectrum of disorders sharing common synuclein pathology. The PLD enzymes are involved in various cellular processes such as vesicular transport, mitogenesis, etc., and a - synuclein and b - synuclein have been identified as specific inhibitors of PLD2.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly links a - synuclein mutations to Parkinson's disease and describes the role of PLD2, which is relevant to the functional assay of a - synuclein mutants' effect on PLD2 inhibition.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study uses an in - vitro assay to measure the inhibition of hPLD2 activity by wild - type and mutant synuclein proteins. The assay measures the release of [3H]choline from lipid vesicles by hPLD2 in the presence of synuclein proteins.",
                    "judgment": "Yes",
                    "reasoning": "The in - vitro assay of hPLD2 inhibition by synuclein proteins effectively models the potential role of a - synuclein in PD pathogenesis as it is related to the PLD2 - related function of a - synuclein.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Basic controls and replicates: Staining of eluates separated by SDS - PAGE with Coomassie brilliant blue showed a 105 kDa protein in infected, but not uninfected, cells (negative control). Wild - type and mutant synuclein proteins were used. The experiments were performed in multiple (three or four) separate experiments (replicates). Variant controls: Known wild - type (negative control) was used as a control.",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "judgment": "Yes",
                    "reasoning": "Both normal (wild - type) and abnormal (A53T itself is a pathogenic mutant) controls were used, and the paper explicitly stated that multiple (three or four) replicates were used for the experiments.",
                    "next_step_or_outcome": "Proceed to Step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Wild - type a - synuclein was used as a control in the assay for A53T.",
                    "sub_step": "3c: Variant Controls",
                    "judgment": "Yes",
                    "reasoning": "A known benign (wild - type) variant was used as a control in the assay for A53T.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "extracted_paper_info": "Statistical analysis of inhibition used the General Linear Model to perform analysis of covariates (ANCOVA) to compare slopes between proteins. However, no OddsPath was calculated in the paper for A53T.",
                    "sub_step": "4a: Statistical Analyses",
                    "judgment": "No",
                    "reasoning": "Although statistical analyses were done, no OddsPath was calculated for A53T.",
                    "next_step_or_outcome": "Proceed to Step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "extracted_paper_info": "The number of benign/pathogenic variant controls used across the entire study for A53T - related assay: Wild - type (benign) was used. So, 1 control in total.",
                    "sub_step": "4b: No OddsPath Calculation",
                    "judgment": "10 or less",
                    "reasoning": "Only 1 variant control (wild - type) was used in the assay related to A53T.",
                    "next_step_or_outcome": "Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for SNCA A53T is rated as PS3_supporting. The disease mechanism of Parkinson's disease related to a - synuclein and PLD2 function was defined. The in - vitro assay was applicable. Basic controls, replicates, and variant controls were used. However, without OddsPath calculation and with only 1 variant control, the maximum strength of evidence is PS3_supporting."
        }
    ]
}